Agoracom Blog Home

Archive for the ‘Medical Marijuana Stocks’ Category

Tetra Bio-Pharma Closes Up 45% To $1.15 On 10.4 Million Shares Traded $TBP.ca

Posted by AGORACOM at 9:57 PM on Tuesday, February 14th, 2017

CLOSING ALERT!!!

TBP:CSE CLOSES UP 45% ON 10.44 MILLION SHARES TRADED!

Tbp large

Close: $1.15 Up: $0.36

Percentage: +45% Volume: 10.44M Shares 

Hub On AGORACOM

Tetra Bio-Pharma Inc. Receives Notice of Authorization from Health Canada for the Conduct of its Clinical Trial with its PPTGR topical product $TBP.ca

Posted by AGORACOM-JC at 8:44 AM on Wednesday, February 1st, 2017

Tbp large

  • Received a Notice of Authorization from the Therapeutic Products Directorate, Health Canada, for its planned clinical trial for PhytoPain Topical Gel Relief
  • Being developed as a locally administered therapeutic for the treatment of Chemotherapy-Induced Neuropathic Pain

OTTAWA, ONTARIO-(Feb. 1, 2017) - PhytoPain Pharma Inc. (“PPP”), a subsidiary of Tetra Bio-Pharma (“Tetra” or the “Company“) (CSE:TBP), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain and other medical conditions announces that it has received a Notice of Authorization from the Therapeutic Products Directorate, Health Canada, for its planned clinical trial for PhytoPain Topical Gel Relief (“PPTGR”), being developed as a locally administered therapeutic for the treatment of Chemotherapy-Induced Neuropathic Pain (“CIPN”).

CIPN is a common adverse effect of cancer therapy and a frequent reason why cancer patients stop their treatment early. For some patients, the severity of the symptoms can be reduced by lowering the dose of chemotherapy or temporarily stopping it. In other patients the symptoms of CIPN may last for months or years after the cancer therapy has stopped. CIPN symptoms are managed using the same analgesics used to manage other types of neuropathic pain. Some of these analgesics also cause intolerable side effects in patients. The use of a topical counterirritant may help reduce the symptoms of CIPN and avoid exposing some patients to oral neuropathic pain analgesics.

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Guy Chamberland
Chief Science Officer
Phone: (514) 220-9225

Tetra Bio-Pharma Inc.
André Rancourt
Chief Executive Officer
Phone: (343) 689-0714

Tetra BioPharma Enters into a Clinical Research Partnership with Sante Cannabis, Quebec’s Leading Medical Cannabis Institution $TBP.ca

Posted by AGORACOM-JC at 9:10 AM on Monday, January 23rd, 2017

Tbp large

  • Entered into a clinical research partnership with Santé Cannabis
  • Santé Cannabis will be working with PPP to develop the late phase clinical trial protocols that will be used to obtain substantial evidence of the safety and efficacy of PPP001 required for a new prescription drug approval from Health Canada and the USA Food and Drug Administration
  • Ground-breaking trials seek to receive the first approval for a Canadian-manufactured cannabis-based prescription medication

OTTAWA, ONTARIO–(Jan. 23, 2017) - PhytoPain Pharma Inc. (“PPP“), a subsidiary of Tetra Bio-Pharma Inc. (“TetraBio” or the “Company” or “TBP“) (CSE:TBP)(CSE:TBP.CN) is pleased to announce that it has entered into a clinical research partnership with Santé Cannabis. Under the partnership, Santé Cannabis will be working with PPP to develop the late phase clinical trial protocols that will be used to obtain substantial evidence of the safety and efficacy of PPP001 required for a new prescription drug approval from Health Canada and the USA Food and Drug Administration (“FDA“). These ground-breaking trials seek to receive the first approval for a Canadian-manufactured cannabis-based prescription medication.

Santé Cannabis is a private clinic specialized in the clinical application of medical cannabis for the treatment of pain and other chronic and terminal health conditions. The clinic’s team of physicians and support staff has unparalleled experience in the assessment and monitoring of medical cannabis patients. Santé Cannabis is the leading medical cannabis research institute in the province of Québec and the primary recruitment site for the province-wide Quebec Cannabis Registry. “Our clinic has provided services to almost 2,000 patients referred by over 1,500 physicians across Québec,” states Erin Prosk, Director of Santé Cannabis. “It is clear that both the medical community and the Quebec patient population are in desperate need of information about the potential benefits and risks of medical cannabis treatments. The status of medical cannabis as an unapproved treatment dissuades many physicians from writing a prescription and requires patients to pay for treatments out of pocket. Of the 2,000 patients that we have seen, there is not one who is not burdened by this financial barrier.”

Dr. Antonio A.L. Vigano, MD, MSc, will lead the Santé Cannabis team to administer the Phase II-III clinical trials in close collaboration with Dr. Irina Kudrina, MDCM, CCFP, CSP, and Santé Cannabis Medical Director Dr. Michael Dworkind, MD, CCFP, FCFP. Dr. Vigano is an attending physician in the Supportive and Palliative Care Service at the McGill University Health Centre and an Associate Professor in the McGill University Department of Oncology. He is the Director of the McGill Nutrition and Performance Laboratory and the Cancer Rehabilitation (CARE) Program. Dr. Vigano has assessed and followed approximately 400 patients during his 18-month tenure at Santé Cannabis. “It has become clear that medical cannabis can be a critical complementary therapy for the treatment of pain,” states Dr. Vigano. “Administering these late phase clinical trials is necessary to rigorously validate the efficacy and tolerability that I observe every day with my patients at Santé Cannabis. If specific medical cannabis products and protocols such as that we will design for PPP001 can withstand the pharmaceutical approval process, it cannot be denied as a valid pain therapy. Cost-coverage should be a logical next step.”

Dr. Irina Kudrina is a McGill-certified pain physician and an attending physician and head of the chronic pain services at the Queen Elizabeth GMF-U and Assistant professor and clinician-researcher at the McGill University Department of Family Medicine. “At present, medical cannabis has already become an important medicine in the fields of oncology, chronic pain, neurology and others. In a clinical review* published in Journal of the American Medical Association (2015), Harvard-based researchers highlighted its use in some medical conditions as being supported by high quality evidence. In Canada, the efforts by regulatory, medical, and pharmaceutical bodies and by the patient advocacy movements have been targeting multiple structural, legal and information barriers still prevailing from the times when long-term high dose opioid therapy was prescribed to chronic pain patients despite its chronic toxicity effects and without high quality evidence for such use. While the clinical use of medical cannabis remains a stigmatized and poorly researched option for some medical conditions, sufficiently large-scale late-phase clinical trials on efficacy, safety and tolerability of medical cannabis are long overdue. These studies might open the door for another class of medications in an attempt to fill the current significant gap for more long-term pharmacological options.”

*(https://www.ncbi.nlm.nih.gov/pubmed/26103031)

PPP entered into this partnership because of Santé Cannabis’ unique expertise and dedication to a pharmacovigilance approach in medicine. The clinic has established clinical practices that help minimize adverse effects in patients and will help design the treatment protocols for the Phase II-III studies. According to Dr. Guy Chamberland, Chief Scientific Officer and Regulatory Affairs, “Adequately designing a late phase clinical trial for the evaluation of the safety and efficacy of inhaled Cannabis requires clinical teams experienced in handling the administration of Cannabis by inhalation to patients. The medical experts of Santé Cannabis complement the scientific and medical experts of our Clinical Advisory Board and provide PPP with an exceptionally solid foundation for the clinical development of Cannabis products as prescription drugs.”

Once authorized by Health Canada, Santé Cannabis will be recruiting participating physicians and patients from the Montreal area throughout 2017. For more information, please contact the clinic by email at info@santecannabis.ca.

About Santé Cannabis:

Santé Cannabis is Québec’s only medical clinic and resource centre dedicated to the clinical practice and research of medical cannabis treatments. Since opening in November of 2014, physicians at Santé Cannabis have assessed almost 2,000 patients referred by more than 1,500 physicians across the province of Québec. Santé Cannabis currently administers several clinical study protocols, including the Québec Cannabis Registry in collaboration with the Research Institute of the McGill University Health Centre and in accordance with the regulations of the Collège des Médecins du Québec.

The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Andre Rancourt
Chief Executive Officer
(613) 421-8402

Tetra Bio-Pharma Inc.
Ryan Brown
VP Business Development and Communications
(613) 421-8402

Tetra Bio-Pharma Inc.
Andre Audet
Executive Chairman
(613) 421-8402

Tetra Bio-Pharma CSO Discussing Task Force Recommendations, DEA — CFN Media $TBP.ca

Posted by AGORACOM-JC at 9:58 AM on Tuesday, January 17th, 2017

Tbp large

  • Exclusive interview covering the effect recent Canadian Cannabis Task Force recommendations and DEA actions could have on Tetra Bio-Pharma Inc.
  • United States government has permitted individual states to legalize the drug, but the Drug Enforcement Administration recently cracked down on cannabidiol (CBD) makers and President Trump’s cabinet picks are opponents of legalization

SEATTLE, WA–(Jan 17, 2017) – CFN Media Group (“CannabisFN”), the leading creative agency and digital media network dedicated to legal cannabis, announces publication of an exclusive interview and story covering the effect recent Canadian Cannabis Task Force recommendations and DEA actions could have on Tetra Bio-Pharma Inc. (OTC PINK: GRPOF) (CSE: TBP) as the company continues development of smokable marijuana as treatment for a variety of conditions.

The United States government has permitted individual states to legalize the drug, but the Drug Enforcement Administration recently cracked down on cannabidiol (CBD) makers and President Trump’s cabinet picks are opponents of legalization. In Canada, voters approved the nationwide legalization of cannabis with the election of Prime Minister Trudeau, but the framework governing the program is only now starting to become clear.

Tetra Bio-Pharma has already started down the pharmaceutical path by undergoing clinical trials for medical cannabis in its natural form. The company believes that smokable marijuana may provide patients with a better natural alternative to synthetic cannabinoids and extracts. With the large number of existing users, the company also has access to a lot of data to support its clinical studies.

In the interview, Tetra’s Chief Science Officer, Dr. Guy Chamberland, points out that medical cannabis patients are keen on receiving reimbursements since they cannot afford regular access without it. At the same time, physicians have been hesitant to prescribe medical cannabis without robust clinical trials demonstrating both safety and efficacy. These demands could lead to a much more ‘pharmaceutical’ approach than existing medical cannabis programs.

Please follow the link to read the full article and see the video interview: http://www.cannabisfn.com/tetra-biopharma-grpof-standing-on-the-right-side-of-regulation-plus-new-interview/

Learn how to become a CFN Media client company, brand or entrepreneur: http://www.cannabisfn.com/become-featured-company/

Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand: https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8

Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone: http://www.cannabisfn.com

About CFN Media
CFN Media (CannabisFN), the leading creative agency and media network dedicated to legal cannabis, helps marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.

CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.

Disclaimer:
Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns CFN Media and CannabisFN.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/.

CFN Media
Frank Lane
206-369-7050
flane@cannabisfn.com

Tetra Bio-Pharma Inc. Announces New Appointment of Dr. Gilles Chamberland, M.D., FRCPC to its Scientific and Clinical Advisory Board $TBP.ca

Posted by AGORACOM-JC at 9:15 AM on Wednesday, January 11th, 2017

Tbp large

  • Announced the nomination of Dr. Gilles Chamberland, MD, FRCPC, to its Scientific and Clinical Advisory Board
  • Board is comprised of experts in clinical research, pain management, cancer, and neurological product drug development

(TORONTO, ONTARIO  Jan. 11, 2017) - PhytoPain Pharma Inc. (“PhytoPain Pharma” or “PPP“), a subsidiary of Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(OTC PINK:GRPOF), is pleased to announce the nomination of Dr. Gilles Chamberland, MD, FRCPC, to its Scientific and Clinical Advisory Board. The board is comprised of experts in clinical research, pain management, cancer, and neurological product drug development. The nomination of Dr. Chamberland, M.D., to its Advisory Board will provide critical guidance on PPP’s clinical development program with regards to the safety of cannabis drug products and the potential mental health risks associated with the consumption of marijuana.

“Patient safety has been a driving force since the creation of PPP. The use of cannabis has been associated with several important safety issues including potential psychiatric-related events. As a company focused on creating scientific data these risks, as well as others, must be adequately assessed and quantified in a clinical environment. The addition of Dr. Gilles Chamberland, M.D., FRCPC, to our team of accomplished scientific and clinical experts will help us ensure that these potential adverse effects of consuming cannabis will be adequately assessed in our clinical development program and these potential risks will be appropriately communicated to both physicians and patients”, stated Dr. Guy Chamberland, Chief Scientific Officer and Regulatory Affairs.

ABOUT Dr. Gilles Chamberland

Dr. Gilles Chamberland, M.D., FRCPC – Director Professional Services, Medical Psychiatrist, Associate Professor, Department of Psychiatry, Institut Philippe-Pinel de Montréal, Université de Montréal.

Dr. Chamberland received a Bachelor of Law degree from the Université de Sherbrooke, a doctorate in medicine from the Université de Montréal, a diploma in psychiatry from the Université de Montréal, and a diploma of advanced studies in biological and medical ethics of the René Descartes University in Paris. In 2012, he earned the Distinguished Fellow from the Canadian Psychiatric Association and, by 2015 the American Psychiatric Association gave him the same professional recognition. He received a diploma in the subspecialty of Forensic Psychiatry in 2013 from the Royal College of Physicians and Surgeons of Canada. Dr. Chamberland has a vast experience in clinical management of patients suffering from various psychiatric conditions including marijuana induced-psychosis. He is also a well-known author and expert witness in the field on psychiatry.

The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Tetra Bio-Pharma Inc.
Andre Rancourt, Chief Executive Officer, or
Ryan Brown. VP Business Development and Communications, or
Andre Audet, Executive Chairman
(343) 689-0714
Investors@tetrabiopharma.com

More than $1 billion of marijuana sold in Colorado in 2016 $TBP.ca $MCOA.us

Posted by AGORACOM-JC at 4:23 PM on Tuesday, December 13th, 2016
Image result for cnn
  • Last year, the marijuana industry created 18,000 full-time jobs and generated $2.39 billion in economic activity in the state.
  • Recreational and medical cannabis shops have sold more than $1 billion of marijuana and related products so far in 2016, already surpassing last year’s total of $996,184,788

(CNN) It’s always 4/20 somewhere — at least in Colorado. The state’s marijuana shops have reached a massive new milestone: $1 billion in legal, regulated sales in the first 10 months of 2016.
Voters legalized marijuana in Colorado back in 2012, but the dispensaries didn’t open until 2014Last year, the marijuana industry created 18,000 full-time jobs and generated $2.39 billion in economic activity in the state.

And the boom is still growing. According to new data from the state’s Department of Revenue, recreational and medical cannabis shops have sold more than $1 billion of marijuana and related products so far in 2016, already surpassing last year’s total of $996,184,788.

Attorney Christian Sederberg, partner at Vicente Sederberg, played an integral part in Colorado’s Amendment 64, which legalized marijuana in the state. He is estimating that sales of pot will reach $1.3 billion by the end of this year, which could have a total economic impact of over $3 billion.
Designer marijuana boosts THC potency
Designer marijuana boosts THC potency 02:24
“This milestone continues to show that the cannabis industry in Colorado is an engine of growth for the economy, a job creator, and one of the biggest industries in the state,” Sederberg told CNN. “People were consuming cannabis before, but now they are buying it from tax-regulated businesses that are benefiting the economy. This has replaced an underground, illegal market.”
Sederberg says that marijuana has become one of the largest industries in Colorado, and certainly the fastest growing.
“From 2015 to 2016, there has been a 53% increase in retail sales and a 9% increase in medical sales,” he said. “Medical sales are growing at a much slower rate, but recreational sales will continue to grow in the double digits.”

All-time high

Marijuana sales in Colorado hit an all-time high in September 2016, generating $127.8 million, according to The Cannabist, a Colorado-based news site covering the industry. But October’s numbers are still sizable: Shops sold nearly $82.8 million of recreational cannabis and $35 million of medical marijuana.
Colorado has three different taxes on recreational marijuana — a standard 2.9% sales tax, a special 10% sales tax, and a 15% excise tax on wholesale transfers, which go towards schools. The state collected just over $6 million from the excise tax, bringing the yearly total to $49.7 million, The Cannabist tallied.
Of that, the first $40 million will go towards school construction projects, and any additional tax revenue from the excise tax will go directly to the state’s public school fund.
In this past election, California, Massachusetts, Nevada, and Maine all approved legal sales of recreational marijuana. Medical marijuana is now legal in more than half of US states. In total, marijuana sales could expand the national market to $21 billion by 2020. That is up from $5.7 billion last year and an expected $7.9 billion this year.
But in the eyes of the federal government, marijuana is still an illegal substance. The Drug Enforcement Administration classifies marijuana as a Schedule 1 drug, the same as heroin, LSD, and ecstasy.
Source: http://edition.cnn.com/2016/12/13/health/colorado-marijuana-sales-trnd/

Tetra Bio-Pharma Provides USA Regulatory Update for its Cannabis Inhalation Product PPP001 $TBP.ca

Posted by AGORACOM-JC at 9:04 AM on Wednesday, November 23rd, 2016

Tbp large

  • Company confirmed that, on November 8, 2016, it received a letter from the Office of Combination Products stating that the USA Food and Drug Administration had completed its review of the request for designation for the marijuana prescription drug and titanium pipe kit
  • FDA confirmed that the product is a combination product, and assigned it to the Center for Drug Evaluation and Research as the lead agency center for premarket review and regulation based on FDA’s determination of the marijuana product’s primary mode of action.

OTTAWA, ONTARIO–(Nov. 23, 2016) - PhytoPain Pharma Inc. (“PPP“), a subsidiary of Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP) (CSE:TBP.CN) (OTC PINK:GRPOF), is a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain and other medical conditions announces that the development of its smoked marijuana prescription drug is on schedule.

The Company confirmed that, on November 8, 2016, it received a letter from the Office of Combination Products stating that the USA Food and Drug Administration (“FDA“) had completed its review of the request for designation for the marijuana prescription drug and titanium pipe kit. The FDA confirmed that the product is a combination product, and assigned it to the Center for Drug Evaluation and Research (“CDER“) as the lead agency center for premarket review and regulation based on FDA’s determination of the marijuana product’s primary mode of action.

The Company previously announced that it received a pre-IND (Investigational New Drug) acknowledgement and meeting request granted letter from the US FDA. This week, the company is submitting the information package required by FDA for the Type B pre-IND meeting in January 2017 with the Division of Anesthesia, Analgesia, and Addiction Products, Center for Drug Evaluation and Research. According to Dr. G. Chamberland, Chief Science Officer, “As per FDA policies, the pre-IND information package is submitted to obtain guidance from FDA on the product development and marketing requirements for the smoked marijuana prescription drug combination product”. Dr. Chamberland further commented that this regulatory filing is part of PPP’s dedication to the commercialization of marijuana as a prescription controlled drug and the corporation’s plan to seek reimbursement by insurers for patients.

The Company has been working with Algorithme Pharma, an Altasciences company, for the conduct of its Phase I clinical trial in healthy human subjects. PPP is using the services of Algorithme Pharma based on its experience and expertise in the conduct of clinical trials for the pharmaceutical industry. Later this week the project team will be submitting the Phase I clinical protocol, and related documents, to the Institutional Review Board for review. If approved, Algorithme Pharma will subsequently submit the Clinical Trial Application to the Therapeutic Products Directorate of Health Canada for approval. In parallel, Algorithme Pharma will submit an application for exemption under section 56 of the Controlled Drugs and Substances Act for its planned research on healthy subjects.

The Company stated that, subsequent to a request for classification to the Medical Devices Bureau, Health Canada, the PPP001-titanium pipe that will be used in the clinical trial is a Class I medical device. Dr. Chamberland commented: “As a Class I medical device, the PPP001-titanium pipe does not require approval for use in the clinical trial”.

About PPP001-kit product

PPP001-kit product will be sold as two separate products packaged together in a single package and is comprised of the drug PPP001 and the device PPP001-titanium pipe. The drug component and device component will be linked together by the labelling of each component.

The product PPP001-kit, once approved, could be sold in pharmacies containing the prescription controlled drug PPP001, in a blister pack, and the PPP-titanium pipe device that will be used to generate the smoke to deliver the active ingredients by inhalation.

PPP001 drug pellet blisters and a fully assembled PPP-titanium pipe for combustion and inhalation of the generated smoke are required for therapy with PPP001 and are provided in the PPP001-kit.

Each blister of PPP001 drug pellet contains marijuana with a standardized amount of delta-9-tetrahydrocannibinol and cannibidiol. A single PPP001 drug pellet is pushed out of the blister by the patient and inserted into the PPP-titanium pipe.

In Other News:

The Company has received $227,738 in exercised warrants for November 2016.

The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Ryan Brown – VP Business Development and Communications
Andre Audet – Executive Chairman
Dr. Guy Chamberland – Chief Scientific Officer
(613) 421-8402

Marijuana Company of America Transitions From the Development Stage to a Revenue Generating Company $MCOA.us

Posted by AGORACOM-JC at 11:10 AM on Thursday, November 17th, 2016

15233_mcoa

  • MCOA has now commenced generating revenue and started to ship orders for its hempSMART Brain product
  • Donald Steinberg, the Company’s CEO, remarked: “Reporting revenue results to our current and prospective shareholders is an important step as the company continues to expand its footprint across America. Now that we have laid the groundwork for our affiliate program in the U.S., MCOA’s goal is to utilize its global contacts and networks to begin to expand the hempSMART brand in other countries. In the past, I have developed one of the largest affiliate marketing programs in the world, with offices in over 50 countries and an affiliate base of over 100,000 members. I will leverage that experience as we expand the hempSMART brand.”

BONSALL, CA–(Marketwired – Nov 17, 2016) –  MARIJUANA COMPANY OF AMERICA INC., (“MCOA” or the “Company”) (OTC PINK: MCOA), an innovative cannabis and hemp development and distribution company, is pleased to announce that after many months of research and product development and business planning, MCOA has now commenced generating revenue and started to ship orders for its hempSMART Brain product.

Donald Steinberg, the Company’s CEO, remarked: “Reporting revenue results to our current and prospective shareholders is an important step as the company continues to expand its footprint across America. Now that we have laid the groundwork for our affiliate program in the U.S., MCOA’s goal is to utilize its global contacts and networks to begin to expand the hempSMART brand in other countries. In the past, I have developed one of the largest affiliate marketing programs in the world, with offices in over 50 countries and an affiliate base of over 100,000 members. I will leverage that experience as we expand the hempSMART brand.”

Tim Altvater, the Company’s marketing director, commented, “The hempSMART product roll-out is a marketer’s dream come true – especially for those of us in the direct sales industry. Now we can focus on the growth of our affiliate network as people begin to use and share their experiences with hempSMART Brain and the benefits of the hempSMART compensation and rewards program. The ability for entrepreneurs to represent the highest quality products, backed by science, to consumers that are in need and seeking them is the driver for our industry’s continued growth and appeal. We’re poised to see unprecedented growth as we finish 2016 strong!”

The Company’s inaugural product, hempSMART Brain, is formulated with CBD or Cannabidiol as the core ingredient combined with high quality branded ingredients to compliment the CBD to support brain health. hempSMART Brain is formulated to meet the growing demand for neutraceutical products that assist in brain function. This is a first-of-its-kind product with a synergistic blend of natural brain support ingredients, blended with water soluble CBD to provide optimal bioavailability for brain support and protection.

Investors are invited to visit the MCOA IR Hub on Agoracom to post questions and receive answers, or review questions and answers already posted by fellow investors. In addition, the MCOA IR HUB provides a monitored forum for investors and prospective shareholders to communicate within a clean, professional environment. Investors can also visit Uptick Newswire’s MCOA Investor Central to learn more about the Company.

About Marijuana Company of America Inc.

Marijuana Company of America (“MCOA”) is a publicly traded company headquartered in Southern California. MCOA will distribute marijuana and products related to marijuana as well as CBD and hemp, using a variety of marketing approaches to distribute on a global basis.

About hempSMART

The hempSMART brand represents MCOA’s non-THC, hemp derived, product line. All hempSMART products are formulated with a cannabinoid base that is derived from hemp and has less than a .3% THC content.

About Club Harmoneous

Club Harmoneous (The Club) delivers all of the benefits of cannabis to its members harmoneously. The Club provides a wide range of cannabis products to its members, medicinal, adult use or healthy foods, body care and cosmetics. The Club products are top-quality and offered to members at competitive prices with the convenience of home delivery.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Marijuana Company of America, Inc. to be materially different from the statements made herein.

LEGAL DISCLOSURE

Marijuana Company of America Inc. will provide management services that assist legal businesses to cultivate, sell, and distribute hemp and marijuana based products within the legal guidelines of individual states and international markets. hempSMART products are derived from Hemp and contain than a .3% THC content.

For more information, please visit the Company’s websites at:
MarijuanaCompanyofAmerica.com
hempSMART.com
Harmoneous.com
Agoracom.com/ir/MarijuanaCompanyofAmerica
UptickNewswire.com/Investor-Central-MCOA
Marijuana Company of America Inc.
Investor Relations
888-777-4362
ir@mcoa.club

Pot stocks soar as legal weed seen surviving Trudeau tax $MCOA.us $TBP.ca

Posted by AGORACOM-JC at 8:54 AM on Thursday, November 17th, 2016
  • Canadian marijuana stocks surged after the head of the country’s biggest producer said his company could cope with taxes as high as 25 per cent, extending a rally that began in the summer with the prospect of legal recreational use.
  • Bruce Linton, chief executive officer of Canopy Growth Corp., says Prime Minister Justin Trudeau’s government will probably choose to control the distribution of legal recreational marijuana through government-run outlets such as liquor stores. A task force is due to report this month on how Canada can build a legal weed market.

“We can probably carry a tax burden of 25 per cent or so and end up in the consumer hands on a still cost-competitive basis, with a superior product,” Mr. Linton said Monday in an interview at Bloomberg’s Ottawa newsroom.

Canopy, based in Smith Falls, Ont., became the first marijuana producer to trade on a major North American stock exchange when it graduated to the Toronto Stock Exchange in July. It became the first publicly traded Canadian producer of the drug in 2014.

The company’s share price more than doubled this month, bringing its market value past $1.6-billion, on better-than-expected earnings and after U.S. elections widened the scope for legal marijuana. The stock was up as much as 33 per cent Wednesday, and was up 5.4 per cent to $14.17 as of 2:10 p.m. Toronto time.

Emerald Health Therapeutics Inc. jumped as much as 62 per cent intraday, and Aurora Cannabis Inc. climbed as much as 50 per cent.

“Anytime there’s more media attention to the sector it brings in more investors,” Jason Zandberg, an analyst covering marijuana producers at PI Financial Corp. in Vancouver, said by phone. “We found that there’s been a lot of interest from U.S. investors. They have a difficulty in investing in the sector given the weird framework that’s in the U.S. where it’s illegal at a federal level.”

Canopy already produces medical marijuana under an existing legal regime. Mr. Linton says the company, which operates out of a former chocolate factory, can shift production to serve the recreational market when Mr. Trudeau’s government makes that legal.

Part of the appeal of the legal variety will be its quality control, Mr. Linton says. “When it’s lawfully available from a reliable supply chain, which we know we can trust and believe in, there are a lot of people who might discontinue the use of say a glass of wine or a beer and try this.”

Canopy can also generate new formulations of medical marijuana to sell through pharmacies as legalization moves ahead, Linton said. Loblaw Cos., owner of the Shoppers Drug Mart pharmacy chain, said Wednesday its is engaging with the government to dispense marijuana from stores.

“There’s a lot of advantages for Canadian producers,” Mr. Zandberg said. Linton “pointed out some key points. I find there’s a lot of interesting aspects to this market that aren’t well known and he definitely highlighted a few that have caused a bit of excitement as well.”

Tetra Bio-Pharma Achieves DTC Eligibility in the United States $TBP.ca

Posted by AGORACOM-JC at 8:35 AM on Wednesday, November 16th, 2016

Tbp_large

  • Effective November 13, 2016, it has secured Depository Trust Company (DTC) eligibility for its common shares listed on the OTCPINK Market
  • Securities that are eligible to be electronically cleared and settled through the DTC are considered “DTC eligible”.

OTTAWA, ONTARIO–(Nov. 16, 2016) - Tetra Bio-Pharma Inc. (“TetraBio” or the “Company“) (CSE:TBP) (CSE:TBP.CN) (OTC PINK:GRPOF) is pleased to announce that effective November 13, 2016, it has secured Depository Trust Company (DTC) eligibility for its common shares listed on the OTCPINK Market.

Securities that are eligible to be electronically cleared and settled through the DTC are considered “DTC eligible”. This electronic method of clearing securities speeds up the receipt of stock and cash and thus accelerates the settlement process for investors.

The Company’s common shares are listed for trading on the OTCPINK, a U.S. based securities trading system, under the symbol “GRPOF”. Tetra Bio-Pharma shares will continue to be traded on the Canadian Stock Exchange under its existing symbol “TBP”.

André Rancourt, Chief Executive Officer, commented, “We’re pleased to announce that our shares have become DTC eligible on the U.S. market and excited to bring our Company to the attention of the investment community in the U.S. We believe that GRPOF offers investors a unique opportunity to invest in a bio pharmaceutical cannabis company before entering clinical trials later this year.

In other company news

Website:

The Company is proud to announce that its website located at www.tetrabiopharma.com is now live. We encourage investors to sign up for news releases and notifications as more information is added to the website.

Industry Participation:

Dr. Guy Chamberland, Chief Scientific Officer and regulatory affairs, and Ryan Brown, co-founder and VP of Business Development, will be presenting at the World of Cannabis business summit in Las Vegas on November 16th 2016. Dr. Chamberland will be presenting as part of “the science of medical cannabis” program while Ryan Brown will be presenting at the “emerging brands investor pitch seminar” more info can be found at www.worldofcannabissummit.com.

Investor Relations:

The Company would like to inform investors that it has engaged Alpha Deal Group LLC, a New York based buy side analyst firm, to perform investor analysis for presentation to its investment network.

As released on November 9, 2016, via CFN (Cannabis Financial Network), the Company has engaged Cannabis Financial Network to increase its visibility in the United States retail investment market.

The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Andre Rancourt
Chief Executive Officer
Phone: (613) 421-8402

Ryan Brown
Co-founder and Director of Communications
Phone: (613) 421-8402

Andre Audet
Executive Chairman
Phone: (613) 421-8402